About the workshop

Given their highly effective nature and simple design, antibody-drug conjugates (ADCs) are a rapidly growing class of therapeutics, particularly for oncology, with over 100 currently in clinical trials. However, selecting high-performing antibody candidates early in the discovery process is crucial to increase the chance of antibody program success. During the workshop, we will explore robust, high-throughout recombinant antibody (rAb) tools using machine learning for screening hundreds to thousands of candidates in parallel to identify new, effective antibody candidates.

What you'll learn about

• ADCs as an emerging option for therapeutic antibodies
• Advantages of high-throughput rAb production using machine learning
• Techniques used to enhance antibody expression (optimization, expression systems, purification strategies, etc.)

About the presenter